Effect of supplementation in treatment of women with polycystic ovary syndrome
Phase 3
Completed
- Conditions
- Polycystic ovary syndrome.Polycystic ovarian syndromeE28.2
- Registration Number
- IRCT201605225623N80
- Lead Sponsor
- Vice chancellor for research, Arak University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 60
Inclusion Criteria
Patients with PCOS according to Rotterdam criteria
Aged 18 to 40 years
Exclusion Criteria
Pregnant women
Adrenal hyperplasia
Androgen-secreting tumors
Hyperprolactinaemia
Thyroid dysfunction
Diabetes or impaired glucose tolerance
Gastrointestinal problems
No hormonal treatments in the previous 6 months in the study
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Expressed levels of PPAR-?. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Expressed levels of GLUT1 gene. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: PCR.;Serum insulin. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Eliza.;Insulin resistance. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Calculation with HOMA formula.
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does Q10 supplementation affect in PCOS patients related to glycemic control and inflammation?
How does Q10 supplementation compare to standard-of-care treatments for PCOS in terms of metabolic and inflammatory outcomes?
Are there specific biomarkers that correlate with improved glycemic control or reduced inflammation in PCOS patients receiving Q10?
What are the potential adverse events associated with Q10 supplementation in PCOS patients and how are they managed?
What combination therapies or alternative compounds show promise in modulating PCOS-related gene expression and inflammation alongside Q10?